AR026901A1 - Peptidos con n-alquilacion que tienen actividad antiangiogenica - Google Patents

Peptidos con n-alquilacion que tienen actividad antiangiogenica

Info

Publication number
AR026901A1
AR026901A1 ARP000106173A ARP000106173A AR026901A1 AR 026901 A1 AR026901 A1 AR 026901A1 AR P000106173 A ARP000106173 A AR P000106173A AR P000106173 A ARP000106173 A AR P000106173A AR 026901 A1 AR026901 A1 AR 026901A1
Authority
AR
Argentina
Prior art keywords
peptides
antiangiogen
rent
activity
angiogenesis
Prior art date
Application number
ARP000106173A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR026901A1 publication Critical patent/AR026901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Péptidos con N-alquilacion de la formula: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11, que tienen utilidad en la inhibicion de la angiogénesis. También se describen composiciones inhibidoras de la angiogénesis y métodos para inhibir la a ngiogénesis en un mamífero.
ARP000106173A 1999-11-22 2000-11-22 Peptidos con n-alquilacion que tienen actividad antiangiogenica AR026901A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44709999A 1999-11-22 1999-11-22
US70264900A 2000-10-31 2000-10-31

Publications (1)

Publication Number Publication Date
AR026901A1 true AR026901A1 (es) 2003-03-05

Family

ID=27034850

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106173A AR026901A1 (es) 1999-11-22 2000-11-22 Peptidos con n-alquilacion que tienen actividad antiangiogenica

Country Status (10)

Country Link
EP (1) EP1242455A1 (es)
JP (1) JP2003514920A (es)
AR (1) AR026901A1 (es)
AU (1) AU1791301A (es)
BR (1) BR0010934A (es)
CA (1) CA2386893A1 (es)
CO (1) CO5261544A1 (es)
HK (1) HK1050902A1 (es)
MX (1) MXPA02005139A (es)
WO (1) WO2001038397A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183242A1 (en) * 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
US7067490B2 (en) 2001-10-31 2006-06-27 Abbott Laboratories Hepta-, Octa-and nonapeptides having antiangiogenic activity
US20030119746A1 (en) * 2001-10-31 2003-06-26 Fortuna Haviv Hepta-and octapeptides having antiangiogenic activity
US7122625B2 (en) 2001-10-31 2006-10-17 Abbott Laboratories Hexa-, hepta-, and octapeptides having antiangiogenic activity
US7037897B2 (en) 2001-10-31 2006-05-02 Abbott Laboratories TRI-, TETRA-, and penta-peptides having antiangiogenic activity
US7001984B2 (en) 2001-10-31 2006-02-21 Abbott Laboratories Di-, tri-, and tetra-peptides having antiangiogenic activity
US7169888B2 (en) 2001-10-31 2007-01-30 Abbott Laboratories Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
US20030125259A1 (en) 2001-10-31 2003-07-03 Fortuna Haviv Octa- and nonapeptides having antiangiogenic activity
US20030228365A1 (en) * 2002-06-07 2003-12-11 Fortuna Haviv Pharmaceutical formulation
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890101A4 (en) * 1996-03-05 1999-12-08 Torrey Pines Inst SELECTIVE N-ALKYLATED PEPTIDOMIMETIC, COMBINATIONAL LIBRARIES AND CORRESPONDING COMPOUNDS
AU724077B2 (en) * 1996-05-03 2000-09-14 Abbvie Inc. Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis
DE69827223T2 (de) * 1997-03-17 2006-02-02 Northwestern University, Chicago Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen

Also Published As

Publication number Publication date
WO2001038397A1 (en) 2001-05-31
EP1242455A1 (en) 2002-09-25
CA2386893A1 (en) 2001-05-31
BR0010934A (pt) 2002-12-17
CO5261544A1 (es) 2003-03-31
JP2003514920A (ja) 2003-04-22
MXPA02005139A (es) 2004-08-23
AU1791301A (en) 2001-06-04
HK1050902A1 (zh) 2003-07-11

Similar Documents

Publication Publication Date Title
HK1057553A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents forthe inhibition of the cell proliferation.
ATE524441T1 (de) Vla-4-inhibitoren
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
WO2002024636A3 (en) N-acylsulfonamide apoptosis promoters
NO20000877D0 (no) Forbedret syrekorrosjonsinhibitor
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20021638L (no) FAB I-inhibitorer
NO20025586D0 (no) Inhibitorer for 11-beta-hydroxy steroid dehydrogenase type 1
PT1165069E (pt) Composicao sinergistica antitumoral
IL148322A0 (en) Benzophenones as inhibitors of reverse transcriptase
DE60009675D1 (de) Protonenpumpinhibitoren enthaltende zusammensetzung
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
TR200200606T2 (tr) Lipaz inhibitörleri içeren dispersiyon terkipleri.
MXPA02012042A (es) Compuestos efectivos como agonistas de beta-2-adrenorreceptor, y como inhibidores de pde4.
MXPA02005067A (es) Composicion inhibidora de la corrosion.
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
PT1232183E (pt) Peptidos possuindo actividade anti-angiogenica
ECSP034634A (es) Inhibidores de la farnesil transferasa
NO20014586L (no) Resorcinol sammensetninger
ATE319689T1 (de) Naphthamidin-urokinasinhibitoren
MXPA03001986A (es) Composiciones antitromboticas.
DE60143740D1 (de) Unsterbliche vaskuläre aventitiale zelllinie
IL132315A0 (en) Compositions comprising oxophosphonate-based metalloproteinase inhibitors
DE69717147T2 (de) Thrombin inhibitoren

Legal Events

Date Code Title Description
FB Suspension of granting procedure